November 05, 2025 08:00 ET | Source: LENZ Therapeutics, Inc. VIZZTM (aceclidine ophthalmic solution) 1.44% received FDA approval for the…
Data shows relationship gap between financial institutions and their customers is holding strong LOUISVILLE, Ky.--(BUSINESS WIRE)--White Clay, a leading provider…
HOUSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, will…
DALLAS, Nov. 4, 2025 /PRNewswire/ -- Nanoscope Therapeutics Inc. announced today positive long-term safety results from its EXTEND study, a…
Resilient results in a complex global environment demonstrate the strength of the company’s financial model and the confidence in its…
BEIJING, Nov. 3, 2025 /PRNewswire/ -- The Annual Conference of Financial Street Forum 2025 concluded on Thursday with a theme…
November 02, 2025 09:00 ET | Source: Belite Bio, Inc MHRA response is based on the Phase 3 DRAGON interim…
Results presented at the 17th World Stroke Congress (WSC 2025) LT3001(Odatroltide)-202 phase 2b study met primary endpoint. No symptomatic intracranial…
A first-of-its-kind tech stack where autonomous AI agents think, decide, and act to drive continuous growth and real business results…
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company…